Recordati S.p.A.
REC.MIDrugs in Pipeline
9
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Q3 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Mercaptamine
Cystinosis
Methadone
Pain Related to Cancer
Silodosin
Benign Prostatic Hyperplasia
Lercanidipine
Essential Hypertension
Rec 0/0438 1 mg or Rec 0/0438 2 mg
Neurogenic Detrusor Overactivity
Pasireotide Diaspartate
Post-Bariatric Hypoglycemia
LCI699
Cushing Syndrome
Udonitrectag
Neurotrophic Keratitis
osilodrostat
Cushing's Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mercaptamine | Phase 3 | Cystinosis | - | - |
Methadone | Phase 3 | Pain Related to Cancer | - | - |
Silodosin | Phase 3 | Benign Prostatic Hyperplasia | - | - |
Lercanidipine | Phase 2 | Essential Hypertension | - | - |
Rec 0/0438 1 mg or Rec 0/0438 2 mg | Phase 2 | Neurogenic Detrusor Overactivity | - | - |
Pasireotide Diaspartate | Phase 2 | Post-Bariatric Hypoglycemia | - | - |
LCI699 | Phase 2 | Cushing Syndrome | - | - |
Udonitrectag | Phase 2 | Neurotrophic Keratitis | - | - |
osilodrostat | Phase 2 | Cushing's Syndrome | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Recordati S.p.A.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Recordati S.p.A.'s (REC.MI) pipeline across Phase 3, Phase 2. Its lead program is Mercaptamine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Recordati S.p.A.'s next FDA catalyst?→
Recordati S.p.A.'s (REC.MI) next tracked catalyst is a Phase 2 expected July 21, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track REC.MI biotech catalysts?→
Add REC.MI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Recordati S.p.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.